Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials-Reference-Cited by-同舟云学术

Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials

Published:2022-05 Issue: Volume:47 Page:101390
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Ranjan Nilesh^ORCID,Chopra Supriya,Mangaj Akshay,Rane Pallavi,Charnalia Mayuri,Kannan Sadhana,Dora Tapas,Engineer Reena,Mahantshetty Umesh,Gurram Lavanya,Mittal Prachi,Ghosh Jaya,Maheshwari Amita,Shylasree TS,Gupta Sudeep,Shrivastava SK

Publisher

Elsevier BV

Subject

General Medicine

Reference15 articles.

1. EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study;Pötter;Lancet Oncol,2021

2. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203;Klopp;J Clin Oncol,2019

3. Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG Oncology RTOG 1203 study;Yeung;J Clin Oncol,2020

4. Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized controlled trial;Chopra;J Clin Oncol,2021

5. Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer;Mayadev;JAMA Oncol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate;International Journal of Radiation Oncology*Biology*Physics;2024-06

2. Longitudinal Costs of Image-Guided Intensity-Modulated Radiation Therapy Versus Three-Dimensional Conformal Radiation: Lessons From Phase III PARCER Trial for Shaping Resource-Stratified Guidelines in Low- and Middle-Income Countries;JCO Global Oncology;2024-03

3. Incidence of vaginal toxicities following definitive chemoradiation in intact cervical cancer: A meta-analysis;Journal of Contemporary Brachytherapy;2024

4. Co-occurrence of symptoms after radiochemotherapy in locally advanced cervix cancer patients: a cluster analysis;Acta Oncologica;2023-10-31

5. Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES);Radiotherapy and Oncology;2022-12